Research Article

A Founder Large Deletion Mutation in Xeroderma Pigmentosum-Variant Form in Tunisia: Implication for Molecular Diagnosis and Therapy

Table 2

Clinical features of Tunisian XP-V patients.

PatientsAffected patientsSexAge (years)Age at onset of the 1st XP macules erythema (years)Geographic
Origin
Age at onset of 1st Tumor in years (Number of tumors) PhotophobiaRadiotherapyTumor post Radiotherapy
BCCSCCOther tumors

XPV6KE1M 47 (died at 50)4Kef22 (6)20 (12)+/−++++++
XPV15GA1F184Gafsa15 (2)16 (2)+/−
XPV17-1 B 3F174 Bizerte000
XPV17-2 BF114000
XPV17-3 BF45000
XP18G1F434Gafsa16 (8)21 (3)KA+/−++++++
XPV20G3F315GafsaND (>10)ND (>2)++++
XPV43-1 7MND5 Zaghouan38 (8)23 (4) KA and Actinic Keratosis+/−+ (local)
XPV43-2F45?541 (1)+/−
XPV48G1F466Gafsa047 (1)+/−
XPV53Z1M507Fahs Zaghouan37 (4)+ (local)+/−
XPV79-13 (1died)F133Tozeur/Gafsa10 (3)KA+++/−
XPV79-2F183KA
XPV91-13F296 TozeurActinic Keratosis
XPV91-2F216
XPV91-3F246

SCC: spino cell carcinoma; BCC: basal cell Carcinoma; KA: kerathoacantum; (+/−) moderate phenotype; (—) absence; (+++) several.